
Lifting & recovery shelf
What I tell clients to look at first. Boring works. The peptides are here so you can see why I say wait.
BPC-157 is a peptide that is research only, not approved for human use in the US.
Also known as Body Protection Compound 157, PL 14736, Bepecin
BPC-157 is a synthetic 15-amino-acid peptide based on a fragment of a stomach protein. It is heavily discussed for tendon, muscle and gut healing because of rodent studies, and it became the center of the 2026 fight over peptide compounding.
In 1 example journal

Not approved for human use in the US. We list it so you can learn what it is, but we do not link to anyone selling it. FDA removed it from the Category 2 "significant safety risk" compounding list on April 15, 2026, and FDA's advisory committee narrowly recommended adding it to the 503A bulks list in July 2026. It is not on that list yet: FDA still has to finish rulemaking, so there is no settled lawful compounding route today. The July 2026 vote was 8-6, reviewed for ulcerative colitis. We will update this status when FDA acts.
As of September 23, 2026.
Key takeaways
Preclinical only: in rat and cell studies, BPC-157 appears to encourage new blood vessel growth and activity in the cells that repair tendons and other tissue. Researchers have proposed pathways involving nitric oxide and growth factor signaling.
FDA's 2026 review says its molecular targets have not been identified and its mechanisms remain poorly understood. None of this has been confirmed in people.


Almost all evidence comes from animal studies, much of it from one research group; human data are limited to very small safety and case reports with no controlled efficacy trials.
Sports medicine reviewers and FDA agree: the animal data are interesting, but there is almost no human evidence on safety or benefit, and products sold online are of unknown quality.
FDA's July 2026 briefing document found no studies giving BPC-157 to humans by the routes it is marketed for, and no information on how it behaves in the human body.
FDA briefing document for the July 2026 advisory committee: BPC-157FDA reviewers also said the substance is not well characterized, testing for impurities and contamination was lacking, and it may pose a significant risk of immune reactions.
FDA briefing document for the July 2026 advisory committee: BPC-157A 2025 systematic review in orthopaedic sports medicine found 36 studies, 35 of them preclinical, and no clinical safety data.
Emerging use of BPC-157 in orthopaedic sports medicine: systematic review (HSS J 2025)USADA says there are no human clinical trials establishing efficacy and it is unknown whether any dose is safe. BPC-157 is named on WADA's 2026 list of non-approved substances.
USADA: BPC-157, prohibited peptideThe FDA advisory committee voted 8 to 6 in July 2026 to recommend adding BPC-157 to the compounding list for ulcerative colitis, after FDA staff recommended against it. The vote is not binding.
McDermott Will & Schulte: PCAC backs majority of peptides in two-day public meeting (July 2026)Summaries of published guidelines, drug labels, regulators and reviews, each attributed to its source. DiscoverMedica does not employ clinicians.
These save with the compound when you add it to My Journal, so they’re on the printout for your visit.
BPC-157 is not approved for human use, so DiscoverMedica links to no seller.
We don’t link to sellers of research-only compounds. Products sold “for research use only” are not made for people and are not held to pharmaceutical quality standards.
It has not been shown to in people. The healing results come from animal studies, and no controlled human trials exist for injuries.
It is not FDA-approved, and it is not on the list of ingredients pharmacies may compound from. Selling it for human use has drawn FDA warning letters.
Not lawfully today. BPC-157 is not FDA-approved, and it is not yet on the list of ingredients pharmacies may compound from, so a licensed telehealth provider has no approved or compounded product to prescribe. An FDA advisory committee voted in July 2026 to recommend adding it, but FDA still has to decide and complete rulemaking. We will update this page if that changes. DiscoverMedica does not link to anyone selling it.
Ask which evidence-based options fit your injury, such as physical therapy, and what to expect from each.
It means the product is not made or tested for people. FDA has sent warning letters to sellers who use that label while making health claims, and says it judges a product by how it is marketed, not by the disclaimer.
BPC-157 is not approved for human use in the US. Not approved for human use in the US. We list it so you can learn what it is, but we do not link to anyone selling it.
This is not a complete list of risks. Talk to a licensed clinician or pharmacist about your own situation. If you have a severe reaction, call 911. You can report side effects to the FDA through MedWatch at 1-800-FDA-1088.
Guide reviewed September 23, 2026.
Educational information only, not medical advice. It does not replace a conversation with a licensed clinician.

What I tell clients to look at first. Boring works. The peptides are here so you can see why I say wait.
A plant compound sold as a supplement for blood sugar and weight. It is not a GLP-1 drug.
A protein supplement made from animal collagen, popular for skin, joints and recovery.
A gentle form of magnesium that people take for sleep and relaxation.
A copper peptide common in skin-care serums. Injectable versions are not approved.